BlackRock Discloses 5.1% Stake in Cue Biopharma
Ticker: CUE · Form: SC 13G · Filed: Feb 7, 2024 · CIK: 1645460
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, insider-buy, biopharma, investment
TL;DR
**BlackRock just revealed a 5.1% stake in Cue Biopharma, a bullish signal for the stock.**
AI Summary
BlackRock Inc., a major investment firm, reported on February 7, 2024, that it holds a significant stake in Cue Biopharma Inc. (NASDAQ: CUE). As of January 31, 2024, BlackRock owns 3,098,804 shares of Cue Biopharma's common stock, representing 5.1% of the company. This matters to investors because it signals that a large, institutional investor sees value in Cue Biopharma, potentially boosting confidence and attracting other investors to the stock.
Why It Matters
This filing indicates a major institutional investor, BlackRock, has taken a substantial position in Cue Biopharma, which can be seen as a vote of confidence in the company's future prospects.
Risk Assessment
Risk Level: low — This filing generally indicates a positive development as a large institution has invested, reducing perceived risk.
Analyst Insight
A smart investor would view BlackRock's 5.1% stake as a positive signal, potentially prompting further research into Cue Biopharma's fundamentals and considering adding it to their watchlist or portfolio.
Key Numbers
- 3,098,804 — Shares Owned (The total number of Cue Biopharma common stock shares BlackRock beneficially owns.)
- 5.1% — Ownership Percentage (The percentage of Cue Biopharma's common stock now owned by BlackRock.)
- January 31, 2024 — Event Date (The specific date BlackRock's ownership crossed the threshold requiring this disclosure.)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Cue Biopharma Inc. (company) — the subject company in which BlackRock invested
- 3,098,804 (dollar_amount) — number of shares of common stock beneficially owned by BlackRock
- 5.1% (dollar_amount) — percentage of class of common stock beneficially owned by BlackRock
- January 31, 2024 (dollar_amount) — date of the event which requires the filing
- February 7, 2024 (dollar_amount) — date the SC 13G filing was made
Forward-Looking Statements
- Other institutional investors may increase their positions in Cue Biopharma, following BlackRock's lead. (Cue Biopharma Inc.) — medium confidence, target: next 3-6 months
- Cue Biopharma's stock price could see a short-term positive reaction due to increased investor confidence. (Cue Biopharma Inc.) — medium confidence, target: next 1-2 weeks
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock, Inc., as stated in the filing under 'Names of reporting persons. BlackRock, Inc.'
What is the name of the issuer whose securities are being reported?
The name of the issuer is CUE BIOPHARMA INC, as indicated under '(Name of Issuer) CUE BIOPHARMA INC'.
What percentage of Cue Biopharma Inc.'s common stock does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 5.1% of the class of common stock, as per the filing's cover page.
How many shares of common stock does BlackRock Inc. beneficially own in Cue Biopharma Inc.?
BlackRock Inc. beneficially owns 3,098,804 shares of common stock in Cue Biopharma Inc., as detailed in the filing's cover page.
What was the date of the event that required this SC 13G filing?
The date of the event which required the filing of this statement was January 31, 2024, as explicitly stated in the filing.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 7, 2024 regarding Cue Biopharma, Inc. (CUE).